The Global Multiple Myeloma Market is projected to grow from USD 21.78 billion in 2024 to USD 40.41 billion by 2033, at a CAGR of 7.11%. Growth is driven by rising disease prevalence, advancements in targeted therapies such as monoclonal antibodies and CAR-T cell therapy, improved diagnostics, and increased healthcare accessibility. Key regions including the U.S., Europe, and Asia-Pacific are seeing heightened therapy adoption. Major pharmaceutical companies like Novartis, Abbvie, Bristol-Myers Squibb, Sanofi, Johnson & Johnson, Pfizer, and Takeda are investing in R&D to develop new treatments. Challenges include high therapy costs, treatment resistance, and significant side effects, which limit access, especially in developing regions.

Barrow, Hanley, Mewhinney & Strauss, a value investing firm based in Dallas, submitted its 13F filing for the second quarter of 2025, detailing changes to its stock portfolio. The firm added significant positions in Capital One Financial Corp (COF), Chevron Corp (CVX), and Sensata Technologies Holding PLC (ST), while increasing stakes in Entegris Inc (ENTG) and SLM Corp (SLM). It also exited holdings in Discover Financial Services (DFS) and Columbia Banking System Inc (COLB), and reduced positions in Elevance Health Inc (ELV) and Jacobs Solutions Inc (J). The portfolio now includes 313 stocks, with notable holdings in Carnival Corp (CCL), Entergy Corp (ETR), Fidelity National Information Services Inc (FIS), Vertiv Holdings Co (VRT), and Merck & Co Inc (MRK). The firm's strategy emphasizes below-market P/E and P/B ratios and above-market dividend yields, reflecting a disciplined value investing approach.

The global high-throughput screening (HTS) market, valued at US$25.7 billion in 2023 and US$28.8 billion in 2024, is projected to grow at a compound annual growth rate (CAGR) of 11.8% from 2024 to 2029, reaching a forecasted valuation of US$50.2 billion by 2029. Growth is driven by increased R&D investments in drug discovery, government funding, and automation in life sciences. Key players include Thermo Fisher Scientific, Agilent Technologies, and Merck KGaA, which offer comprehensive HTS solutions. The market is supported by innovations in automation, miniaturization, and high-content screening, with the consumables segment dominating due to recurring demand. North America leads the market, while Asia Pacific is expected to grow fastest, benefiting from strong pharmaceutical capabilities and government support. Institutional grants, such as a USD 7.8 million award to the University of Pittsburgh, highlight growing investment in drug discovery research.

Deutsche Bank has reduced its price target for Merck KGaA from EUR140.00 to EUR133.00, maintaining a Buy rating after the company reported mixed second-quarter results. The bank believes that despite a weakened guidance and investor concerns over Merck's group structure, there remains underlying value in the company, particularly in its Life Science business, with potential for stabilization in the third quarter due to improving performance and attractive valuation.

The global stem-cell manufacturing market is experiencing rapid scale-up to meet growing demand across therapeutic, research, and banking sectors. In 2024, the market was valued at approximately USD 16.23 billion and is projected to reach USD 40.40 billion by 2032, growing at a CAGR of 11.5%. North America currently holds the largest market share (~40%) due to strong regulatory frameworks and biopharmaceutical infrastructure, while the Asia-Pacific region is emerging as the fastest-growing with a CAGR of ~14%, driven by policy reforms in Japan and China, healthcare expansion, and scale advantages. Key growth drivers include automation using closed-system bioreactors, public-private funding initiatives like NIIMBL and Japan's conditional approval pathway, rising prevalence of chronic diseases, and increased public awareness through organizations like ISCT. Major players include Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group Ltd., DH Life Sciences, LLC, Sartorius AG, Becton, Dickinson and Company (BD), Eppendorf SE, Corning Incorporated, Bio-Rad Laboratories, Inc., and Fujifilm Holdings Corporation (Cellular Dynamics). Challenges include high capital and operating costs, regulatory complexity across regions, and supply chain bottlenecks such as sourcing fetal bovine serum and skilled bioprocess engineers. The market is expected to nearly triple over the next decade, with strategic opportunities in outsourced manufacturing (CMOs), vertical integration in regenerative therapies, and distributed manufacturing models, particularly in Asia-Pacific.